Candel Therapeutics (CADL) Chief Commercial Officer Sims listed in Form 3

Rhea-AI Filing Summary

Candel Therapeutics, Inc. filed a Form 3 identifying Mark E. Sims as an officer of the company, serving as Chief Commercial Officer. The filing does not report any share transactions or holdings for Sims, and the transaction summary shows no purchases, sales, exercises, gifts, or other movements.

Key Figures

Reported purchases: 0 shares Reported sales: 0 shares Derivative transactions: 0 transactions +1 more

4 metrics

Reported purchases 0 shares BuyShares in transaction summary

Reported sales 0 shares SellShares in transaction summary

Derivative transactions 0 transactions derivativeTransactionCount in summary

Net buy/sell shares 0 shares netBuySellShares marked neutral

Key Terms

Chief Commercial Officer, Form 3, derivativeTransactionCount

3 terms

Chief Commercial Officer financial

"officer_title": "Chief Commercial Officer""

A chief commercial officer (CCO) is the senior executive responsible for a company’s revenue-generating activities, including sales, marketing, pricing, customer relationships and business development. Think of the CCO as the head coach who builds the game plan to win customers and grow sales; their effectiveness affects how fast a company earns money, enters new markets and sustains profits, making the role a key signal for investors about future revenue and competitive strength.

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

derivativeTransactionCount financial

""derivativeTransactionCount": 0"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 07/08/2026 - 04:11 PM Accepted by SEC EDGAR 07/08/2026 - 04:11 PM Learn about SEC filing dates

FAQ

What does Candel Therapeutics' Form 3 for Mark E. Sims show?

The Form 3 identifies Mark E. Sims as Chief Commercial Officer of Candel Therapeutics, Inc. It reports no stock purchases, sales, option exercises, gifts, or other equity transactions in this filing.

Does the CADL Form 3 report any share transactions by Mark E. Sims?

No, the Form 3 transaction summary shows zero purchases, zero sales, zero exercises, zero gifts, and no other equity movements for Mark E. Sims in this filing.

What is Mark E. Sims’ role at Candel Therapeutics (CADL)?

Mark E. Sims is reported as an officer of Candel Therapeutics, Inc. with the title Chief Commercial Officer, indicating a senior leadership role focused on the company’s commercial activities.

Does the Candel Therapeutics Form 3 disclose any beneficial ownership details?

The structured data lists no transactions and indicates zero holding entries, so this particular Form 3 does not provide specific share ownership amounts for Mark E. Sims.

Are there any derivative securities reported for Mark E. Sims in this Form 3?

No, the derivative summary is empty and derivativeTransactionCount is zero, indicating no options, warrants, or other derivative securities are reported for Mark E. Sims in this filing.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Sims Mark E.

(Last) (First) (Middle)

C/O CANDEL THERAPEUTICS, INC.

117 KENDRICK STREET, SUITE 450

(Street)

NEEDHAM MASSACHUSETTS 02494

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/06/2026

3. Issuer Name and Ticker or Trading Symbol
Candel Therapeutics, Inc. [ CADL ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Charles Schoch, as Attorney-In-Fact for Mark E. Sims	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)